[Information Sharing] Report on Major Animal Epidemics Nationwide in October 2024

Source: Animal Husbandry and Veterinary Bureau, Ministry of Agriculture and Rural Affairs

In October 2024, a total of 23 major animal epidemics of Categories I, II, and III were reported nationwide, affecting 100,152 animals (heads/birds/individuals/horses) and resulting in 11,318 deaths. Among these, one Category I epidemic was reported, involving two affected animals with no fatalities; 15 Category II epidemics were reported, affecting 27,512 animals and causing 3,919 deaths, with porcine epidemic diarrhea, brucellosis, and duck plague accounting for the top three in terms of reported cases, together representing 86.79% of all Category II epidemic reports; and seven Category III epidemics were reported, affecting 72,638 animals and resulting in 7,399 deaths, with coccidiosis in chickens, swine influenza, and pasteurellosis ranking as the top three in terms of reported cases, collectively accounting for 97.57% of all Category III epidemic reports.

Note: The statistical data in this table are derived from reports submitted by provinces, autonomous regions, municipalities directly under the central government, and the Xinjiang Production and Construction Corps on occurrences of major animal epidemics classified as Category I, II, and III.

When looking for animal disease testing reagents, choose the Weiboxin brand.

Be aware of Weiboxin Bio All products of!

Official consultation phone numbers: 020-66377266 / 135 3988 6748, Ms. Dai

Guangzhou Weiboxin Biotechnology Co., Ltd. is located in the national-level innovation park—Guangzhou Science City—and is a provincial-level “Little Giant” high-tech enterprise specializing in the forward R&D, manufacturing, sales, and technical services of diagnostic reagents for animal epidemics. The company is also recognized as a “Contract-Honoring and Credit-Keeping Enterprise” in Guangdong Province and a provincial demonstration unit for intellectual property, as well as a industry–university–research collaboration base of Guangdong Food and Drug Vocational College and an executive director unit of the Veterinary Diagnostic and Biological Products Committee of the Guangdong Society of Animal Husbandry and Veterinary Medicine. It has been designated as an innovative, high-potential enterprise by multiple research institutes, including the Entrepreneurship College of Jinan University in Guangdong Province, and has been awarded the titles of “Specialized, Refined, Distinctive, and Innovative” enterprise at both municipal and provincial levels. The company has received the “Most Investment-Valuable Enterprise” award and the annual title of “ASF and Swine Disease Testing Service Provider.” In addition, it has obtained veterinary drug product approval numbers from the Ministry of Agriculture and Rural Affairs: Veterinary Drug Registration No. 191438923 (Fluorescent PCR Test Kit for African Swine Fever Virus), Veterinary Drug Registration No. 191438213 (ELISA Antibody Test Kit for Porcine Reproductive and Respiratory Syndrome Virus), and Veterinary Drug Registration No. 191438875 (Blocking ELISA Antibody Test Kit for Classical Swine Fever Virus). The company was awarded the Excellence Prize in the Growth Category of the Biopharmaceutical Industry at the 11th China Innovation and Entrepreneurship Competition, the Provincial Second Prize in the Growth Category of the Nanotechnology Industry Technology Competition within the Science and Technology Innovation and Entrepreneurship Contest, and the National Third Prize in the Growth Category of the National Finals of the Nanotechnology Industry Technology Innovation Special Competition at the China Innovation and Entrepreneurship Competition. Furthermore, it has consecutively received the A-level Tax Credit Honor Certificate, the Four-Star Trademark Brand Certification, and the Two-Integration Management System Assessment Certificate each year, along with ISO 9001 International Quality Management System Certification, ISO 14001 International Environmental Management System Certification, and GMP certification from the Ministry of Agriculture. Since its establishment, the company has been granted a total of 24 patents, including 5 invention patents, 15 utility model patents, and 4 design patents, as well as more than ten trademarks.

The company boasts robust technical capabilities and a team of world-class professionals, including dozens of masters, doctors, and returnees who studied abroad, as well as numerous senior-title technical experts. Currently, the company’s primary focus is on the research and development of molecular diagnostic reagents. Its core R&D team has developed more than 600 products spanning molecular diagnostics and immunoassays, including public-health–oriented fluorescent PCR test kits, animal disease–control–oriented fluorescent PCR test kits, clinical and research–grade fluorescent quantitative PCR kits, and transgenic identification test kits (ZL2006). The company has also established a nationwide distribution network covering more than ten major cities, such as Beijing, Shanghai, Hangzhou, Nanjing, Xi’an, Chongqing, Lanzhou, Zhengzhou, and Qingdao.

Looking ahead, Weiboxin will remain steadfast in its commitment to continuously enhance product quality and service standards. Leveraging a rapid and efficient research platform and abundant biomedical resources, we will conduct extensive and in-depth R&D and scientific research in the biomedical field, thereby contributing to human health and advancing life sciences. Quality is our lifeline, and innovation is our soul; we will unwaveringly uphold this philosophy as we strive to become the premier supplier of rapid diagnostic reagents and instruments.